American Bio Medica Appoints New Vice President of U.S. Sales and Marketing.

Business Editors

KINDERHOOK, N.Y.--(BUSINESS WIRE)--Sept. 27, 2000

American Bio Medica Corp. (NASDAQ:ABMC), which develops, manufactures and markets drugs of abuse diagnostic kits, sprays and support services, today announced the appointment of Jim McMenamin to the position of Vice President of U.S. Sales and Marketing.

Mr. McMenamin will be responsible for all sales and marketing aspects of the ABMC core product line, the Rapid Drug Screen(TM). Mr. McMenamin replaces a U.S. National Sales Manager and a Director of National Accounts.

Mr. McMenamin joins American Bio Medica Corporation from Biostar, Inc., a subsidiary of Thermo Electron group, a point of care medical biotechnology company. At Biostar, Mr. McMenamin held the position of Vice President of Worldwide Marketing and was responsible for all aspects of international marketing, distribution and acquisitions of product line extensions.

Prior to his position at Biostar Inc., Mr. McMenamin was Director of Marketing and Sales for Murex Diagnostics Inc., a $100+ million manufacturer of clinical diagnostic products for microbiology and infectious disease that was acquired by Abbott Laboratories (NYSE:ABT) in April 1998. At Murex, he was responsible for all aspects of sales and marketing for a $35 million U.S. market.

"We are very excited about Jim joining the ABMC management team," stated ABMC Chairman and CEO Stan Cipkowski. "The combination of his extensive sales and marketing experience with his knowledge of the medical diagnostics markets will enable him to implement sales and marketing programs and devise strategies that will consistently grow our sales, ultimately making our goal of profitability in the current fiscal year a reality."

American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate on-site drugs-of-abuse diagnostic kits, sprays and support services worldwide. The company's global distributors target the workplace, physicians, corrections, clinical and educational markets. ABMC's Drug Detector(TM) identifies minute traces of illegal drugs on surfaces, while the company's Rapid Drug Screen tests individuals and is proven to correlate 100% with the standard laboratory screening test.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.